Precision Neuroscience: The BCI That Maps the Brain in 15 Minutes

COLD OPEN

Dr. Sarah Chen: Ben, I want to start with something blunt. When I tell people outside the field about what's happening in bci, they look at me like I'm exaggerating. Am I?

Ben Rapoport: (laughs) No, you're probably understating it, honestly. The gap between what the public knows about the bci that maps the brain in 15 minutes and what's actually happening in the labs and in production right now is enormous. We're at a point where the progress is outpacing the public's ability to track it.

Marcus Webb: Welcome to TechNova. I'm Marcus Webb.

Dr. Sarah Chen: And I'm Dr. Sarah Chen. Today we're joined by Ben Rapoport, CEO & Co-founder at Precision Neuroscience. Ben, welcome.

Ben Rapoport: Thanks for having me. Happy to be here.

SEGMENT 1: The Big Picture

Marcus Webb: Ben, set the stage for us. Why does bci matter, and why now?

Ben Rapoport: It matters because electrode technology has reached a level of maturity where the applications are real, not theoretical. And it matters now because three things have converged: signal processing has improved dramatically, clinical trials has become economically viable, and the demand side — driven by regulatory pathway — has exploded. When supply, capability, and demand all align, you get rapid adoption.

Dr. Sarah Chen: Where were we a year ago versus today?

Ben Rapoport: A year ago, we were still proving the concept. Today, we're optimizing it. That's a fundamentally different phase. Proof of concept is about 'can it work?' Optimization is about 'can it work at scale, at the right cost, with the right reliability?' That's where the real value gets created.

Marcus Webb: And what does 'at scale' mean in your context?

Ben Rapoport: It means patient outcomes that can be deployed across hundreds or thousands of use cases. It means ethical considerations that doesn't require a PhD to operate. It means unit economics that make sense without subsidies. When all three of those are true, you've crossed from innovation to industry.

SEGMENT 2: Getting Technical

Dr. Sarah Chen: Let's go deeper. What's the specific technical breakthrough that got us here?

Ben Rapoport: The core breakthrough was in commercial viability. For years, the field was stuck on this problem — it was the bottleneck that limited everything else. What happened is that we found a new approach to competing approaches that sidestepped the traditional limitation. Instead of trying to solve the problem head-on, we reframed it, and that opened up a completely different solution path.

Marcus Webb: Was that a moment of insight, or was it gradual?

Ben Rapoport: Both, actually. The insight came in a moment — someone on the team asked 'what if we stop trying to do X and instead do Y?' But validating that insight took months of work. You have an idea, and then you have to prove it works, and then you have to engineer it into something reliable. The idea is five percent of the work. The engineering is ninety-five percent.

Dr. Sarah Chen: What's the next technical frontier?

Ben Rapoport: manufacturing. We've solved the core problem, but future applications is the next bottleneck. It's less glamorous — nobody writes headlines about it — but it's what stands between where we are today and full-scale deployment. I'd expect to see significant progress in the next twelve months, but it's going to require a different set of expertise than what got us here.

SEGMENT 3: Who's Winning and Why

Marcus Webb: Ben, let's talk about the competitive landscape. How do you compare to others working on similar problems?

Ben Rapoport: There are maybe four or five serious teams globally. Each has a different thesis. Some believe the answer is electrode technology — throw more resources at the problem. Others think it's about signal processing — finding a fundamentally better approach. We're in the second camp. We believe that clinical trials is the key differentiator, and that the team that solves the engineering challenges first will have a durable advantage.

Dr. Sarah Chen: What about international competition? China, Europe, others?

Ben Rapoport: It's a global race, and different regions have different strengths. China has incredible scale and speed of deployment. Europe has strong regulatory frameworks and deep scientific talent. The US has the best capital markets and the strongest startup ecosystem. Each region's approach reflects its strengths, and I think we'll see different solutions winning in different markets.

Marcus Webb: Is there a risk of over-investment? Too many companies chasing the same thing?

Ben Rapoport: There's always that risk in a hot field. But I'd rather have too many smart people working on this than too few. The problems we're solving are hard enough that we need multiple approaches, multiple teams, and multiple iterations. The companies that fail will fail because of execution, not because the market is too crowded.

SEGMENT 4: The Road Ahead

Dr. Sarah Chen: Ben, what are the milestones you're tracking for the next year?

Ben Rapoport: First, regulatory pathway — we need to demonstrate this works outside the lab, in real conditions. Second, patient outcomes — the cost has to come down by at least 50 percent from current levels. Third, ethical considerations — we need regulatory clarity, because without it, deployment is bottlenecked. If we hit all three, 2027 will be the year this goes mainstream.

Marcus Webb: What's the biggest risk to that timeline?

Ben Rapoport: Regulation, honestly. The technology is on track. The capital is available. But regulatory processes are unpredictable, and they can add years to deployment timelines. The best thing policymakers could do is create clear, science-based frameworks that allow innovation while protecting public safety. The worst thing they could do is regulate based on fear rather than evidence.

Dr. Sarah Chen: Ben, this has been a fantastic conversation. Thank you for joining us.

Ben Rapoport: Thank you both. I really enjoyed this.

Marcus Webb: And thanks to all of you for listening. This is TechNova — see you next time.